FDA Approves BELSOMRA® (suvorexant) for the Treatment of Insomnia

Dateline City: WHITEHOUSE STATION, N.J. BELSOMRA expected to be available in late 2014 or early 2015 WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved BELSOMRA® (suvorexant) for adults with insomnia who have difficulty falling asleep and/or staying asleep. BELSOMRA (pronounced bell-SOM-rah) is a highly selective antagonist for orexin receptors. Orexin is a neurotransmitter found in a specific part of the brain that can help keep a person awake. Language: English Contact: MerckMedia Contacts:Pam Eisele, 267-305-3558Megan Wilkinson, 267-305-6463orInvestor Contacts:Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Source: Merck.com - Product News - Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news